Efficacy of short‐course lansoprazole with clarithromycin and amoxicillin in the eradication of Helicobacter pylori in South‐East Asian patients: 5‐day t.d.s. versus 7‐day b.d. treatment regimens

K. Goh, P. Cheah, Ym Tan, M. Rosmawati, K. Ong, Lo Yl, S. Chin
{"title":"Efficacy of short‐course lansoprazole with clarithromycin and amoxicillin in the eradication of Helicobacter pylori in South‐East Asian patients: 5‐day t.d.s. versus 7‐day b.d. treatment regimens","authors":"K. Goh, P. Cheah, Ym Tan, M. Rosmawati, K. Ong, Lo Yl, S. Chin","doi":"10.1046/J.1443-9573.2001.00043.X","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To determine and compare the efficacy of 5-day t.d.s and 7-day b.d. treatment regimens comprising lansoprazole, clarithromycin and amoxicillin in the eradication of Helicobacter pylori. \n \n \n \nMETHODS: Patients with unequivocal evidence of H. pylori infection based on histology and rapid urease tests of both antrum and corpus biopsies were recruited for the study. The study was a randomized, investigator-blind, comparative study. Patients received either 500 mg clarithromycin t.d.s. and 500 mg amoxicillin t.d.s. for 5 days (LAC5) or 500 mg clarithromycin b.d. and 500 mg amoxicillin b.d. for 7 days (LAC7) together with 30 mg lansoprazole (both groups) daily for either 5 or 7 days, depending on the treatment group. Patients were assessed for the successful eradication of H. pylori, defined as the absence of bacteria based on histology and urease tests on both antral and corporeal biopsies, carried out at least 4 weeks after completion of the therapy. \n \n \n \nRESULTS: One hundred and eight patients were recruited for the study. In the LAC5 treatment group, four patients failed to return for follow up and in the LAC7 group, two failed to return for follow up and two were not compliant with medications. Eradication rates based on an intention-to-treat analysis were: 46/54 for LAC5 (85.2%; 95% CI = 72.9–93.4) and 47/54 for LAC7 (87.0%; 95% CI = 75.1–94.6). Based on a per protocol analysis, the rates were: 46/50 for LAC5 (92.0%; 95% CI = 80.8–97.8) and 47/50 for LAC7 (94.0%; 95% CI = 83.5–98.7). Both treatment regimens were convenient for patients and except for two patients in the LAC7 group, all patients reported taking 100% of all prescribed medications. The side-effects encountered were uniformly mild and no patient discontinued treatment because of intolerance to medications. The most common side-effects were altered taste (LAC5 64.7%; LAC7 78.8%). Diarrhea, nausea and anorexia were reported in a minority of patients. \n \n \n \nCONCLUSIONS: Both the LAC5 t.d.s. and the LAC7 b.d. treatment regimens were well tolerated by patients and were highly effective in the eradication of H. pylori.","PeriodicalId":10082,"journal":{"name":"Chinese journal of digestive diseases","volume":"202 1","pages":"137-141"},"PeriodicalIF":0.0000,"publicationDate":"2001-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of digestive diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1443-9573.2001.00043.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

OBJECTIVE: To determine and compare the efficacy of 5-day t.d.s and 7-day b.d. treatment regimens comprising lansoprazole, clarithromycin and amoxicillin in the eradication of Helicobacter pylori. METHODS: Patients with unequivocal evidence of H. pylori infection based on histology and rapid urease tests of both antrum and corpus biopsies were recruited for the study. The study was a randomized, investigator-blind, comparative study. Patients received either 500 mg clarithromycin t.d.s. and 500 mg amoxicillin t.d.s. for 5 days (LAC5) or 500 mg clarithromycin b.d. and 500 mg amoxicillin b.d. for 7 days (LAC7) together with 30 mg lansoprazole (both groups) daily for either 5 or 7 days, depending on the treatment group. Patients were assessed for the successful eradication of H. pylori, defined as the absence of bacteria based on histology and urease tests on both antral and corporeal biopsies, carried out at least 4 weeks after completion of the therapy. RESULTS: One hundred and eight patients were recruited for the study. In the LAC5 treatment group, four patients failed to return for follow up and in the LAC7 group, two failed to return for follow up and two were not compliant with medications. Eradication rates based on an intention-to-treat analysis were: 46/54 for LAC5 (85.2%; 95% CI = 72.9–93.4) and 47/54 for LAC7 (87.0%; 95% CI = 75.1–94.6). Based on a per protocol analysis, the rates were: 46/50 for LAC5 (92.0%; 95% CI = 80.8–97.8) and 47/50 for LAC7 (94.0%; 95% CI = 83.5–98.7). Both treatment regimens were convenient for patients and except for two patients in the LAC7 group, all patients reported taking 100% of all prescribed medications. The side-effects encountered were uniformly mild and no patient discontinued treatment because of intolerance to medications. The most common side-effects were altered taste (LAC5 64.7%; LAC7 78.8%). Diarrhea, nausea and anorexia were reported in a minority of patients. CONCLUSIONS: Both the LAC5 t.d.s. and the LAC7 b.d. treatment regimens were well tolerated by patients and were highly effective in the eradication of H. pylori.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
短期兰索拉唑联合克拉霉素和阿莫西林根除东南亚患者幽门螺杆菌的疗效:5天t.d.s vs 7天b.d.治疗方案
目的:确定并比较兰索拉唑、克拉霉素和阿莫西林组成的5天t / d和7天b / d治疗方案根除幽门螺杆菌的疗效。方法:根据胃窦和体活检的组织学和快速脲酶试验,招募有明确证据的幽门螺杆菌感染的患者进行研究。该研究是一项随机、研究者盲、比较研究。患者每日接受500 mg克拉霉素和500 mg阿莫西林联合治疗5天(LAC5)或500 mg克拉霉素和500 mg阿莫西林联合治疗7天(LAC7)以及30 mg兰索拉唑(两组)治疗5天或7天,具体取决于治疗组。评估患者是否成功根除幽门螺杆菌,定义为在治疗完成后至少4周进行的胃窦和身体活检的组织学和脲酶测试中没有细菌。结果:108名患者被纳入研究。在LAC5治疗组中,4例患者未能返回随访,在LAC7治疗组中,2例患者未能返回随访,2例患者不遵医嘱。基于意向治疗分析的根除率为:LAC5为46/54 (85.2%;95% CI = 72.9-93.4)和47/54 (87.0%;95% ci = 75.1-94.6)。根据每个协议分析,LAC5的发生率为46/50 (92.0%;95% CI = 80.8-97.8)和47/50 (94.0%;95% ci = 83.5-98.7)。两种治疗方案对患者都很方便,除了LAC7组的两名患者外,所有患者都报告100%服用了所有处方药物。所遇到的副作用都很轻微,没有患者因为对药物不耐受而停止治疗。最常见的副作用是味觉改变(LAC5 64.7%;LAC7 78.8%)。少数患者出现腹泻、恶心和厌食。结论:LAC5 t.d.s.和LAC7 b.d.s.治疗方案均具有良好的耐受性,且在根除幽门螺杆菌方面非常有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Prospective randomized clinical trial of two drug delivery pathway in the treatment of inoperable advanced pancreatic carcinoma. Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone. Prevalence and risk factors of Helicobacter pylori infection in healthy schoolchildren. Association of peptic ulcer with increased expression of Lewis antigens, but not vacuolating cytotoxin activity or babA2 gene status, in Helicobacter pylori strains from China. Accuracy of endoscopic ultrasound staging of gastric cancer in routine clinical practice in Singapore.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1